M
MicroSintesis
MicroSintesis – A life sciences company pioneering gut health in animals through proteobiotics.
About MicroSintesis
Microsintesis is a pioneering company in the animal health sector, focusing on enhancing gut health through the use of proteobiotics, a next-generation probiotic technology. The company primarily serves the livestock and pet markets, offering specialized products for pigs and dogs. Microsintesis operates in the life sciences market, targeting veterinarians, livestock farmers, and pet owners who are looking for advanced solutions to improve animal health. The business model revolves around the development, production, and sale of proteobiotic-based products, such as Ygia for dogs and Nuvio for swine. These products are designed to rebalance gut flora, providing a first line of defense against harmful bacteria and promoting overall gut health. Revenue is generated through direct sales and partnerships with veterinary clinics and agricultural businesses.
Source: Dealroom company dataAt a glance
- Founded
- 2011
- Headquarters
- Charlottetown, Canada
- Sector
- Food
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Northern Private Capital (NPC)
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MicroSintesis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MicroSintesis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.